Prognostic performance of multiple biomarkers in patients with acute coronary syndrome without standard cardiovascular risk factors

Le Wang, Hongliang Cong, Jingxia Zhang, Ximing Li, Yue‐cheng Hu, Chen Wang, Jia-chun Lang, Bing-Yang Zhou, Tingting Li, Chunwei Liu, Hua Yang, Libin Ren, Wei Qi, Wenyu LiFrontiers in Cardiovascular Medicine 2022 · DOI

Abstract

Fibrinogen, D-dimer, NT-proBNP, and Lp(a) provide valuable prognostic information for major adverse cardiovascular events (MACE) when applied to patients with acute coronary syndrome (ACS) who lack standard modifiable cardiovascular risk factors (SMuRFs). A multimarker strategy, combining these biomarkers to reflect different pathophysiological processes alongside traditional clinical factors, significantly improves cardiovascular risk stratification in this challenging population.

Introduction

Most patients who suffer from Acute Coronary Syndrome (ACS) present with at least one of the "big four" standard modifiable cardiovascular risk factors (SMuRFs): smoking, diabetes, hypertension, or hypercholesterolemia. However, up to 15% of ACS patients present with none of these. These "SMuRF-less" patients pose a significant clinical challenge; because they lack traditional red flags, they may be perceived as lower risk, yet they often experience higher rates of mortality and recurrent events. This study investigates whether circulating biomarkers can fill this diagnostic gap by providing a clearer picture of the underlying pathophysiological processes—such as inflammation and coagulation—driving their disease.

Methods and Study Population

The researchers conducted a retrospective, observational study at Tianjin Chest Hospital, screening 35,432 consecutive ACS patients treated between January 2014 and December 2017. The cohort was narrowed to 621 patients who lacked all four SMuRFs and had complete follow-up data.

Figure 1: Flowchart of the selection process and study population definition.

Seven candidate biomarkers were initially evaluated: hs-CRP, Fibrinogen, D-dimer, NT-proBNP, Lp(a), Uric Acid, and GGT. The primary endpoint was MACE, defined as cardiovascular death, myocardial infarction, or stroke, over a median follow-up period of 5 years.

Key Results and Insights

Of the seven markers analyzed, four remained independent predictors of MACE after adjusting for age, gender, and heart function (LVEF): Fibrinogen, D-dimer, NT-proBNP, and Lp(a). Among these, D-dimer showed the strongest association, suggesting that activated coagulation pathways play a dominant role in disease progression for patients lacking traditional metabolic risks.

The risk of a major event increased dramatically with the number of elevated biomarkers. A patient with four elevated markers was six times more likely to experience MACE than a patient with none (Adjusted Hazard Ratio: 6.008).

Figure 2: Kaplan-Meier survival curve for MACE according to the number of elevated biomarkers.

Predictive Accuracy

Standard clinical metrics like Left Ventricular Ejection Fraction (LVEF) and kidney function (eGFR) provided a baseline C-statistic of only 0.592. Integrating the multimarker score boosted this to 0.711 ($P < 0.001$), representing a substantial leap in predictive accuracy. The Net Reclassification Index (NRI) was 0.549 ($P < 0.001$), indicating that the model correctly moved a large portion of patients into more accurate risk categories.

Discussion and Limitations

This study identifies specific thresholds for risk in SMuRF-less patients: Fibrinogen $\ge$ 3.26 g/L, D-dimer $\ge$ 0.87 ug/ml, NT-proBNP $\ge$ 169 pg/ml, and Lp(a) $\ge$ 77.9 mmol/L. While the multimarker score is statistically significant, the authors note that as a retrospective, single-center study, these findings require validation in larger, multi-ethnic prospective cohorts. Additionally, because biomarkers were only measured once at admission, future research into dynamic changes over time may provide even greater prognostic value. Despite these limitations, the multimarker strategy offers a robust path forward for identifying high-risk individuals who might otherwise be overlooked by traditional risk models.

Summary updated

Abstract

Fibrinogen, D-dimer, NT-proBNP and Lp(a) provided valuable prognostic information for MACE when applied to patients with ACS without SMuRFs. The multimarker strategy, which combined multiple biomarkers reflecting different pathophysiological process with traditional risk factors improved the cardiovascular risk stratification.
BibTeX
@inproceedings{wang2022prognostic,
  author = {Le Wang and Hongliang Cong and Jingxia Zhang and Ximing Li and Yue‐cheng Hu and Chen Wang and Jia-chun Lang and Bing-Yang Zhou and Tingting Li and Chunwei Liu and Hua Yang and Libin Ren and Wei Qi and Wenyu Li},
  title = {{Prognostic performance of multiple biomarkers in patients with acute coronary syndrome without standard cardiovascular risk factors}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2022},
  doi = {10.3389/fcvm.2022.916085},
}
Figure